Tirzepatide 10mg Research Peptide with 99% Purity and COA Report by Janoshik

Tirzepatide 20mg Research Peptide with 99% Purity and COA Report by Janoshik

Tirzepatide 40mg Monthly subscription

Original price was: $520.00.Current price is: $300.00. / month

Compound: Tirzepatide (Dual GIP / GLP-1 Receptor Agonist)

Concentration: 10mg per vial

Format: Lyophilized White Powder (Strictly for In-Vitro Laboratory Use)

Chemical Classification: Unimolecular Dual Incretin Agonist

Chemical Profile: Tirzepatide is a synthetic, linear polypeptide comprising 39 amino acids. It functions as a unimolecular dual agonist with high affinity for both the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor and the Glucagon-Like Peptide-1 (GLP-1) receptor. Structurally, it is an analogue of the native GIP sequence, modified to include a C20 fatty di-acid moiety. This acylation facilitates high-affinity binding to plasma albumin, which significantly extends its half-life and stability in research substrates compared to native incretins.

Mechanism: Synergistic Dual Agonism (GIP/GLP-1)
Sequence: Modified GIP backbone with C20 fatty acid side chain
Molecular Weight: ~4,813.53 g/mol

Dual Receptor Synergy Tirzepatide is the primary reference standard for investigating the synergistic effects of simultaneous GIP and GLP-1 receptor activation. Research utilizes this peptide to compare the efficacy of dual-agonism versus selective GLP-1 receptor agonism. Laboratory models focus on how the addition of GIP signaling amplifies metabolic regulatory pathways that are otherwise limited in single-receptor models.
Beta-Cell Function & Insulinotropic Signaling In studies regarding pancreatic islet function, Tirzepatide is observed to enhance insulin secretion from beta-cells in a glucose-dependent manner. Simultaneously, it is investigated for its role in suppressing glucagon secretion from alpha-cells. This “dual-action” mechanism is a key subject of research for understanding the stabilization of glucose homeostasis under hyperglycemic conditions.
Adiposity & Lipid Metabolism Preclinical models of metabolic dysfunction utilize Tirzepatide to study lipid utilization. Research indicates that the GIP component may directly influence adipocyte (fat cell) metabolism, potentially improving insulin sensitivity and lipid buffering capacity. Studies focus on the peptide’s ability to modulate adiponectin levels and increase energy expenditure, providing data on the reversal of diet-induced obesity phenotypes.
Gastric Motility & Nutrient Kinetics Similar to selective GLP-1 agonists, Tirzepatide is used to model the regulation of gastric emptying. Researchers utilize this compound to measure the rate of nutrient absorption and its downstream effects on post-prandial glycemic excursions. This mechanism is critical for studying the “ileal brake” phenomenon and gut-brain signaling axes.
Neuroendocrine Pathways Tirzepatide is investigated for its interaction with central nervous system receptors located in the hypothalamus. Research aims to map the neural circuits responsible for appetite regulation and satiety, specifically looking at how dual receptor activation influences hedonic feeding behaviors in rodent models.

Important Notices:

Research Use Only: This product is sold strictly for scientific research and development purposes.
Handling: The product is provided as a lyophilized powder. Reconstitution requires bacteriostatic water and sterile laboratory equipment (syringes, needles, alcohol pads), which are not included.
Visuals: Vial appearance and cap color may vary from product photos; the label quantity refers to the total active content inside the vial.

Disclaimer: This product is sold explicitly as a chemical reagent for laboratory research and testing purposes only. It is not intended for human consumption, diagnostic, or therapeutic use. Bodily introduction of any kind into humans or animals is strictly forbidden by law.